Adjuvanted or whole-virion vaccine for 2009 influenza A (H1N1)

The Lancet Infectious Diseases

Volumn 11, Issue 7, 2011, Pages 496-497

  Barrett, P Noel ^a   Ehrlich, Hartmut J ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE;

DRUG EFFICACY; DRUG TOLERABILITY; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LETTER; PRIORITY JOURNAL; VIRION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; DISEASE OUTBREAKS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; YOUNG ADULT;

EID: 79959293286     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70155-4     Document Type: Letter

References (7)

1. Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11:91-101.
2. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375:1100-1108.
3. Ikonen N, Strengell M, Kinnunen L, et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill 2010, 15. pii 19478.
4. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
5. Palache AM, Brands R, van Scharrenburg GJ Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997, 176(suppl 1):S20-S23.
6. Haeberer M, Rolland M, Seyler T. Impact of the pandemic influenza A(H1N1)v vaccination campaign in Jersey, 2009-2010. European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE); Lisbon; Nov 11-13, 2010. 20100401 (abstr).
7. Barrett PN, Berezuk G, Fritsch S, et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.